Connbey said on an interactive platform on July 20 that at this stage, the company has no plans to market enteritis as a drug in the US.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.